Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200149 | 0.90 | ALDH1A1 (0.82) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23200122 | 0.89 | ALDH1A1 (0.80) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23199939 | 0.89 | ALDH1A1 (0.80) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23199988 | 0.88 | ALDH1A1 (0.79) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23200158 | 0.87 | ALDH1A1 (0.77) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23200234 | 0.87 | ALDH1A1 (0.77) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23200047 | 0.86 | ALDH1A1 (0.76) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL23200062 | 0.86 | ALDH1A1 (0.76) | ALDH1A1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL23200086 | 0.86 | ALDH1A1 (0.76) | ALDH1A1NPSR1MAPTSMN1; SMN2ATM | |
| SCHEMBL23200243 | 0.84 | ALDH1A1 (0.72) | ALDH1A1NPSR1MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | claimed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | claimed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| EP-3802503-A1 | UREA DERIVATIVE MODULATORS OF TRYPTOPHAN CATABOLISM | E-Therapeutics plc (GB) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | ALDH1A1 606/4885NPSR1 786/4885MAPT 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.